Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients

The Outcomes of Lung Transplantation in Patients With Bronchiectasis and Antibody Deficiency

“…It is well established that early episodes of acute rejection, CMV, and recurrent infections lead to obliterative bronchiolitis. [23][24][25] Optimal use of IVIG in suitable patients may lead to improved outcome after transplantation by reducing infection and rejection rates and thus obliterative bronchiolitis.…”

Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology

“…210,211 The development of hyperimmune anti-CMV IGIV preparations provides an alternative to polyclonal IGIV preparations; however, anti-CMV IGIV alone did not prevent CMV-induced viremia or interstitial pneumonitis or deaths at 1 year in a series of seropositive lung transplant recipients. 212 This is unfortunate, considering the increasing incidence of ganciclovir-resistant CMV in some bone marrow and organ transplant centers.…”

Combined CMV Prophylaxis Improves Outcome and Reduces the Risk for Bronchiolitis Obliterans Syndrome (BOS) after Lung Transplantation

“…Taking into consideration that neither GAN nor CMV-IG alone was able to sufficiently prevent CMV disease in CMV mismatched lung transplant recipients, as demonstrated by Kruger and Palmer, combined regimens require further investigation (8,9). Furthermore, based on the findings of animal studies, combined use of GAN and CMV-IG may act synergistically and are able to reduce CMV-related mortality (10).…”